Barclays analyst Matt Miksic maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $85.00. The company’s shares closed yesterday at $61.73.
Miksic covers the Healthcare sector, focusing on stocks such as Medtronic, Globus Medical, and LivaNova. According to TipRanks, Miksic has an average return of 6.9% and a 60.11% success rate on recommended stocks.
In addition to Barclays, Globus Medical also received a Buy from Stifel Nicolaus’s Mathew Blackman in a report issued yesterday. However, today, JMP Securities reiterated a Hold rating on Globus Medical (NYSE: GMED).
Based on Globus Medical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $616.53 million and a net profit of $15.03 million. In comparison, last year the company earned a revenue of $274.5 million and had a net profit of $50.06 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical (GMED) Company Description:
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
